disAMR Emerges to Combat Antimicrobial Resistance Through Strategic Acquisition and Advocacy

disAMR: A New Force Against Antimicrobial Resistance

On February 24, 2026, disAMR, a newly formed company led by Brammer Bio co-founders Mark Bamforth OBE and Dr. Richard Snyder, announces its acquisition of AMR Insights, a prominent communications hub established to combat antimicrobial resistance (AMR). This acquisition reflects disAMR's strategic commitment to tackling one of the most pressing public health threats of our time, which the World Health Organization links to over 1.27 million direct deaths and nearly 5 million associated mortalities from 2019 alone. With projections indicating that AMR could lead to nearly 2 million annual deaths by 2050, disAMR frames its mission as crucial not only for immediate health outcomes but also for long-term societal welfare.

DisAMR aims to unify and mobilize stakeholders through educational initiatives, advocacy, and the promotion of innovative solutions targeted at antibiotic resistance. Bamforth emphasizes the urgency of a cohesive platform to better streamline efforts and facilitate dialogue among various players in the health ecosystem. Current conditions, marked by insufficient funding and market inefficiencies in antibacterial development, necessitate a robust approach to catalyze new ideas and products that can address the growing crisis. The integration of AMR Insights into disAMR is designed to harness an extensive library of educational resources while creating a multichannel platform that enhances the collaboration necessary for innovative solutions.

Both founders recognize the fragmented landscape of AMR research and the critical need for unified efforts in combating the stigma surrounding infections. Dr. Snyder expresses a sense of optimism that the relaunch of AMR Insights under disAMR will not only improve stakeholder engagement but also steer policy reforms and funding approaches towards more sustainable antibiotic development. The resolve to reshape the narrative around AMR indicates a shift towards more active advocacy and community involvement, essential for generating the necessary momentum in fighting this existential threat.

In tandem with this strategic acquisition, disAMR is committed to addressing the gaps historically evident in AMR research. By fostering dialogue and incentivizing collaboration among academia, industry, and policymakers, disAMR lays the groundwork for innovative pharmacological solutions to emerge. Furthermore, a focus on educating the public and enhancing awareness about AMR is expected to galvanize community support essential for enduring progress.

As the global health landscape evolves, disAMR’s initiatives represent a concerted effort to eradicate the barriers to innovation and funding that have hindered progress in combatting antimicrobial resistance. Through focused advocacy, streamlined education, and collaborative research efforts, disAMR positions itself as a key player in the global response to one of the most urgent health challenges facing society today.